Opthea Announces Positive Phase One Trial Results
The first-in-human ongoing clinical trial of OPT-302,
The first-in-human ongoing clinical trial of OPT-302,
Associate Professor Mark Daniell will become President
Children around the world who are disadvantaged
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
